The role of SLAMF7 in multiple myeloma: impact on therapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Clinical Immunology

• Publication date

  2017-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/1744666X.2016.1209112PMID 27376202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

  2016influential reference
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

  2016influential reference
• Treatment of relapsed and refractory multiple myeloma

  2016cited by this paper
• Treatment of relapsed and refractory multiple myeloma

  2016cited by this paper
• Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

  2015cited by this paper
• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

  2015cited by this paper
• Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

  2015influential reference
• Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

  2015cited by this paper
• Monoclonal antibodies in myeloma.

  2015cited by this paper
• Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

  2015influential reference
• Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015influential reference
• Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

  2015cited by this paper
• Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

  2015influential reference
• Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

  2015cited by this paper
• CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cited by this paper
• Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

  2014cited by this paper
• Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

  2014cited by this paper
• Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

  2014cited by this paper
• Abstract 2563: Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma

  2014cited by this paper
• SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).

  2014cited by this paper
• CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma

  2013cited by this paper
• Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

  2013cited by this paper
• Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

  2013cited by this paper
• Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

  2013cited by this paper
• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.

  2013cited by this paper
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

  2013cited by this paper
• Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

  2012cited by this paper
• Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

  2012cited by this paper
• Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

  2012cited by this paper
• The role of natural killer cells in immunity against multiple myeloma

  2012cited by this paper
• Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management

  2012cited by this paper
• Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

  2012cited by this paper
• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  2012cited by this paper
• A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

  2012influential reference
• Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

  2012influential reference
• Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

  2012cited by this paper
• ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).

  2012influential reference
• Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

  2011cited by this paper
• Monoclonal antibodies in the treatment of multiple myeloma

  2011cited by this paper
• Antibody-Based Therapies in Multiple Myeloma

  2011cited by this paper
• SLAM family receptors and SAP adaptors in immunity.

  2011cited by this paper
• Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

  2010cited by this paper
• Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

  2010cited by this paper
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

  2009cited by this paper
• Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

  2009cited by this paper
• Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

  2009cited by this paper
• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

  2008influential reference
• CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

  2008influential reference
• A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

  2007cited by this paper
• Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.

  2007cited by this paper
• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

  2006cited by this paper
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  2006cited by this paper
• A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

  2006cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function.

  2002cited by this paper
• Cutting Edge: Activation of NK Cell-Mediated Cytotoxicity by a SAP-Independent Receptor of the CD2 Family1

  2001cited by this paper
• Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma.

  1999cited by this paper

• SLAMF7 improves the efficacy of PD-1 immunotherapy by enhancing T cell response in non-small cell lung cancer.

  2026cites this paper
• The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy.

  2025cites this paper
• Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma

  2024cites this paper
• Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

  2024cites this paper
• Clinical Advances in CAR T Cell Therapies for the Patients with Multiple Myeloma

  2023cites this paper
• Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer

  2022cites this paper
• Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma

  2020cites this paper
• CAR T cell therapies for patients with multiple myeloma

  2020cites this paper
• KINETIC MODELING AND ITS APPLICATION IN THE BIOPHARMACEUTICAL INDUSTRY

  2018cites this paper
• Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy

  2018cites this paper
• High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma

  2018cites this paper
• Screening of Monoclonal Antibodies for Cancer Treatment

  2018cites this paper
• 新型免疫肿瘤治疗临床研究现状及应用前景

  2017cites this paper
• Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials

  2017cites this paper
• Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer

  2017cites this paper
• Talin-1 interaction network promotes hepatocellular carcinoma progression

  2017cites this paper